Candida albicans is an important pathogenic fungus of humans, causing a range of infections. These infections are usually treated with antifungal drugs that target sterol metabolism. Resistance to these antifungals can result from overexpression of sterol biosynthetic genes. Therefore it is of interest to understand transcriptional regulation of sterol biosynthesis in C. albicans. Recently two reports [Silver, Oliver and White (2004) 
such as caspofungin (see [2] for a recent review of C. albicans drug resistance). The polyenes and azoles both target ergosterol, the major sterol in the fungal plasma membrane, analogous to cholesterol in mammalian membranes. Both ergosterol and cholesterol are synthesized by the same pathway. The polyenes and azoles are fungal-specific because they exploit differences between the two biosynthetic pathways.
The azoles such as FLC work by inhibiting lanosterol demethylase (Erg11p), the product of the ERG11 gene in S. cerevisiae and C. albicans. When Erg11p is inhibited, ergosterol in the plasma membrane is replaced by methylated sterols. This alters the fluidity of the membrane and alters the function of integral membrane proteins, including chitin synthetase that is important for cell growth and division.
C. albicans cells are able to develop resistance against the azole drugs in several ways, including mutation or overexpression of ERG11, the gene encoding the target enzyme Erg11p, or overexpression of the genes for either of the two types of efflux pumps: (i) MDR1 which is the gene for a major facilitator pump dependent on the proton motive force of the plasma membrane to move molecules or (ii) CDR1 and CDR2, genes encoding ATP-binding cassette (ABC) transporter pumps that use cellular ATP to move molecules across the plasma membrane.
S. cerevisiae sterol regulation
Because overexpression of ERG11 is a mechanism of azole resistance in C. albicans, it was of interest to determine how ERG11 expression is regulated in C. albicans, using S. cerevisiae as a model (summarized in [3, 4] ). In S. cerevisiae, ergosterol biosynthesis has been studied in some detail, although its regulation is not well understood. What is understood is that S. cerevisiae encodes at least 30 transcription factors that include a zinc/cysteine [Zn(2)Cys(6)] finger domain near the N-terminus that is important for binding to response elements in the promoters of genes regulated by these factors. These transcription factor proteins also include an activator domain at the C-terminus that is not well understood. Two Zn(2)Cys(6) transcription factors are known to be important in S. cerevisiae sterol regulation, encoded by UPC2 and ECM22. UPC2 was first identified for its alteration of sterol uptake under anaerobic conditions (uptake of cholesterol). Fungi import sterols under anaerobic conditions because oxygen is needed by ERG11 during lanosterol demethylation. Therefore sterols can only be synthesized under aerobic conditions, and the cells must rely on uptake under anaerobic conditions. The other gene, ECM22, was first identified for its effect on cell-wall stability, specifically Calcofluor White hypersusceptibility (extracellular matrix). It now appears that the changes in cell-wall stability include both alterations in the cell wall and alterations in sterol metabolism with associated changes in the cell wall.
Further work with the S. cerevisiae genes UPC2 and ECM22 has shown that both genes have similar, overlapping functions. Both genes up-regulate ERG genes including ERG2 and ERG3 (both downstream of ERG11). This upregulation is mediated through an SRE (sterol response element) located in the promoter of these ERG genes. The SRE is 11 bases long, with a strongly conserved core of 7 bases. Characterization of the UPC2 deletion has shown that it affects sterol synthesis through the ERG genes, and sterol uptake, possibly mediated through genes such as DAN1 and TIR under anaerobic conditions. However, the effect of UPC2 on anaerobic growth is not well characterized. The UPC2 gene deletion is also hypersusceptible to the azole ketoconazole. A mutation in UPC2 (upc2-1) causes hyperactivation of the transcription factor, resulting in overexpression of pumps associated with sterol uptake.
The gene deletion for ECM22 does have effects on sterol biosynthesis. However, the major phenotype of the gene deletion is that it is hypersusceptible to cycloheximide. The double mutant ( upc2 ecm22) has been reported by some laboratories but has been noted as inviable by others.
Models of activation
The current model for S. cerevisiae Zn(2)Cys(6) transcription factors is that the N-terminal DBD [DNA-binding domain; including the Zn(2)Cys(6) finger] and the C-terminal activation domain work together to activate genes containing the SRE. However, the method of activation of the factor is not known.
An alternative model for activation of genes by UPC2 and ECM22 is based on analogy (but no homology) to the mammalian sterol regulation. In this model, the N-terminal DBD with its Zn(2)Cys(6) finger is normally localized to the cytoplasm and ER (endoplasmic reticulum) because the transmembrane domains are part of the C-terminal activation domain of the proteins. By analogy with mammalian cells, the sterols in the ER membrane prevent the transcription factor from entering the nucleus and activating genes. In low sterols, the ER localization of the factor is destabilized, and specific proteases cleave the N-terminal DBDs from the C-terminal transmembrane domains. This frees the DBD, with its nuclear localization sequences, to enter the nucleus and activate the genes. There is limited evidence for either model of activation. There are two different reports of protein localization of S. cerevisiae UPC2 and ECM22 in the absence of activation. In the absence of drug, YPL.db (Yeast Protein Localization database) shows clear localization of Upc2p in the cytoplasm, while http://yeastgfp.ucsf.edu suggests that Upc2p and Ecm22p are in the nucleus. There are no reports of protein localization in the presence of drugs.
C. albicans UPC2: two reports
The possible role of UPC2 and ECM22 homologues in C. albicans is clearly clinically important as ergosterol biosynthesis and metabolism are clearly central to the interaction of azole drugs with the fungal cells, and their subsequent effectiveness in treating the patient. In C. albicans, there is only one Zn(2)Cys(6) transcription factor with homology to UPC2 and ECM22 of S. cerevisiae. The C. albicans gene is known as UPC2 as it is slightly more homologous to S. cerevisiae UPC2 than to S. cerevisiae ECM22. The most likely explanation for two genes in S. cerevisiae and one gene in C. albicans is that an ancestor of S. cerevisiae is known to have duplicated the entire genome, with subsequent gene loss. This genome duplication is known to have occurred after S. cerevisiae and C. albicans diverged from each other.
This C. albicans UPC2 gene has recently been studied by two groups, Silver et al. [3] and MacPherson et al. [4] . The two studies have considerable data in agreement and both have unique aspects that further our understanding of this gene. Both publications will be discussed in detail below. The similarities and differences between the papers reinforce our understanding of ergosterol metabolism.
Gene disruptions
Both groups have constructed gene disruptions. Silver et al. [3] used a multiply marked strain BWP17 and were able to delete the two alleles of UPC2 in the diploid strain. MacPherson et al. [4] used an unrelated strain, SGY-243 that contained four alleles of the UPC2 gene. Most C. albicans strains come from clinical isolates and it is not unusual for individual strains to be polysomic for one or more chromosomes. Both groups introduced the UPC2 gene back into their homozygous deletions. Silver et al. [3] introduced one copy of the UPC2 gene back at its original location, under the control of its endogenous promoter. The group actually created two reconstructions, in which the UPC2 gene was placed into each of the two allelic promoters. One promoter is more active than the other and this difference was observed in several phenotypic characterizations. MacPherson et al. [4] inserted a UPC2 gene into the homozygous deletion although the gene was integrated at an unrelated chromosomal location and was driven by an inducible promoter. While the overexpressor gives us additional information (see below), it does not restore the original phenotype, consistent with overexpression of the gene.
Drug susceptibilities
Changes in drug susceptibility are the most clinically relevant effects of these UPC2 deletion strains. MacPherson et al. [4] used dotting of serial dilutions to show that the homozygous deletion was hypersusceptible to the azoles FLC and ketoconazole, with some suggestion of a change in susceptibility to fluphenazine, a drug known to induce expression of the efflux pumps CDR1 and CDR2. These determinations were performed in both rich and minimal media.
Silver et al. [3] performed drug susceptibility testing using clinically approved methods, adapted for use with a wide variety of drugs and strains with auxotrophies. These investigators demonstrated that the homozygous deletion strain was hypersusceptible to three azoles (FLC, ketoconazole and itraconazole), three other drugs that inhibit other enzymes in the ergosterol pathway (terbinafine, fenpropimorph and lovastatin), and two drugs associated with chitin metabolism (nikkomycin Z and Calcofluor White). These last two drugs are significant as the S. cerevisiae ECM22 was isolated for hypersusceptibility to Calcofluor White. Silver et al. [3] did not see a change in susceptibility to the polyene AmB, to cycloheximide (unlike the S. cerevisiae ECM22 deletion), or to dithiothreitol or SDS, two compounds that affect the cellwall stability. In addition, preliminary results suggest that the deletion is not altered in susceptibility to the echinocandin caspofungin (P.M. Silver and T.C. White, unpublished work).
In general, Silver et al. [3] found that their reconstructions restored drug susceptibility to wild-type levels, dependent on the allele promoter that was driving the expression of the gene. MacPherson et al. [4] used the overexpressor construct integrated at a different locus (RP10) to show that overexpression of the UPC2 gene confers resistance to FLC, ketoconazole and fluphenazine. However, the overexpression levels of the gene or protein were not documented.
Sterol characterization of the mutants
MacPherson et al. [4] further characterized their homozygous deletion to show that it has impaired growth in anaerobic non-supplemented media, which is consistent with the requirement for anaerobic cells to import their sterols.
Silver et al. [3] further characterized their mutant to show that the homozygous deletion has reduced levels of ergosterol, most likely the result of reduced sterol biosynthesis and reduced sterol uptake. This is consistent with the drug hypersusceptibility tests, except for the lack of change in AmB susceptibility. In addition, the investigators monitored uptake of radiolabelled cholesterol, showing that the gene deletion accumulates less radiolabelled cholesterol than the wild-type or reconstructed strains. This is problematic as the experiments were performed aerobically, where sterol uptake is inhibited in S. cerevisiae, and the uptake was for cholesterol, not ergosterol. (labelled ergosterol is not commercially available). Consistent with cholesterol uptake, the homozygous deletion also demonstrated reduced uptake of two lipophilic dyes, phloxine B and Congo Red. Importantly, Congo Red is another marker for cell-wall stability.
Northern-blot analyses
Both groups used Northern-blot analysis to demonstrate that the ERG genes are regulated by UPC2, using ACT1 (actin) as a probe for loading and for lack of regulation. MacPherson demonstrated that ERG2, ERG7, ERG11 and ERG25 were regulated by UPC2 as they are not induced by azoles in the UPC2 homozygous deletion. Silver et al. [3] obtained similar results for ERG2 and ERG11. Both groups show that UPC2 expression was up-regulated by azole drugs. Of course, the gene expression cannot be monitored in the homozygous deletion by Northern blot, but both groups suggested that UPC2 is self-regulated. Both groups induced expression using 5 µg/ml FLC, a level of drug approx. 4-8-fold above the MIC (minimum inhibitory concentration) for FLC for wild-type strains. Furthermore, the two datasets were obtained at different times, 1 and 24 h for MacPherson et al. [4] and 5 h for Silver et al. [3] which demonstrates the extended times at which the up-regulation occurs.
Promoter analyses
The two groups analysed the promoters of several C. albicans ERG genes for SRE elements, using two different methods. MacPherson looked for degenerate homology to the 11 bp SRE from S. cerevisiae and found the sequence in the promoters of ERG2, ERG7, ERG11, ERG25 and UPC2. Silver et al. [3] searched the promoters of the ERG genes for exact matches to the 7 bp core sequence. They found the conserved core 7 bp, in either direction, upstream of 13 of 21 genes involved in ergosterol synthesis. Preliminary Northern-blot analysis has confirmed the UPC2 regulation of many of these genes, and has demonstrated that some of the other genes may have cryptic SRE sites or that those other genes are regulated through an intermediate (P.M. Silver and T.C. White, unpublished work). The 7 bp core sequences were not found in the promoters of housekeeping genes.
Protein-DNA interactions
MacPherson analysed the DBD in greater detail by expressing the domain (amino acids 1-148) in Escherichia coli as a fusion, and binding the fusion protein to DNA sequences. They show that the DBD binds to each of the three SRE elements they identified in the C. albicans ERG2 promoter. The gel shifts are specific for the recombinant protein and are eliminated when the DNA sequence is mutated, suggesting that the binding is specific. The strongest binding was observed to element C in this promoter, which has the best homology to the 7 bp core, suggesting that both groups are on the right track to predicting genes regulated by this transcription factor.
These two sets of data contribute greatly to our understanding of the regulation of sterol metabolism in C. albicans, perhaps giving us a better understanding in C. albicans than we have in S. cerevisiae. Several aspects of UPC2 regulation remain to be investigated: (a) to accurately define the SRE in C. albicans, and determine how it differs from S. cerevisiae, (b) to identify the set of genes regulated by UPC2, including ERG genes and genes in other pathways (which have not been explored in either analysis), (c) to determine the role of the C-terminal activation domain including its transmembrane domains -does it keep the protein in the cytoplasm or is it important for gene activation and (d) to determine how the UPC2 is activated in response to sterol starvation -is it proteolytic cleavage and subsequent import analogous to mammalian sterol regulation, or is the activation domain altered for activation (phosphorylation or dephosphorylation, cleavage, altered structure etc.)? These questions are likely to be answered by these two groups who have given us new insights into the regulation of UPC2 by sterols and the subsequent effects on sterol metabolism and drug susceptibility in this pathogenic fungus.
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